Recent breakthrough research reveals that 6 SL muscle atrophy prevention may offer a promising approach to maintaining muscle strength and function throughout the aging process. As scientists uncover the molecular mechanisms behind age-related muscle loss, a natural compound originally found in human milk is emerging as a powerful ally in the fight against sarcopenia.
The Growing Burden of Muscle Loss
If you’ve noticed it’s harder to climb stairs, carry groceries, or maintain your balance as you’ve gotten older, you’re not alone. Starting around age 30, adults naturally begin losing 3-5% of their muscle mass per decade. This gradual decline accelerates after age 60, when the rate of muscle loss intensifies dramatically.
Sarcopenia—the medical term for age-related muscle loss—affects an estimated 10-20% of older adults, with rates climbing to 11-50% among those over 80. This isn’t just about aesthetics or athletic performance. Muscle loss directly impacts your independence, increasing the risk of falls, fractures, hospitalization, and reduced quality of life. The personal and societal costs are staggering, making the search for effective interventions more urgent than ever.
Understanding How Muscles Waste Away
To appreciate how 6′-sialyllactose (6′-SL) helps prevent muscle atrophy, it’s essential to understand what happens at the cellular level when muscles break down.
Your body constantly balances two opposing processes: building new muscle proteins (synthesis) and breaking down old ones (degradation). When degradation outpaces synthesis, muscle atrophy occurs. The primary system responsible for this breakdown is called the ubiquitin-proteasome pathway—think of it as your body’s recycling center for damaged or unneeded proteins.
Two key proteins act as master regulators of this degradation process: MuRF1 (muscle RING-finger protein-1) and atrogin-1. When these proteins increase, they signal your muscles to break down faster. This happens in many conditions: prolonged bed rest, chronic illness, aging, certain medications, and even the stress hormone dexamethasone.
Scientists often use dexamethasone to study muscle atrophy because it reliably triggers these degradation pathways, mimicking what happens in sarcopenia and various muscle-wasting conditions.
The 6′-SL Discovery: A Natural Defender Against Muscle Loss
Enter 6′-SL, a human milk oligosaccharide (HMO) that has captured scientific attention for its remarkable effects on muscle health. While HMOs were originally recognized for supporting infant development, researchers have discovered that 6′-SL offers benefits well beyond infancy.
In groundbreaking 2024 research, scientists investigated whether 6′-SL could prevent dexamethasone-induced muscle atrophy—both in cultured muscle cells and living mice. The results were striking.
When muscle cells were exposed to dexamethasone, they showed classic signs of atrophy: reduced size, fewer muscle fibers, and dramatic increases in MuRF1 and atrogin-1. But when 6′-SL was added alongside the dexamethasone, these harmful changes were significantly blocked.
How 6′-SL Protects Your Muscles
The research revealed that 6′-SL works through multiple complementary mechanisms to support muscle strength:
Blocking Protein Degradation Signals
6′-SL directly inhibits the increase of myostatin, MuRF1, and atrogin-1—the trio of proteins that trigger muscle breakdown. By keeping these degradation signals in check, 6′-SL helps maintain the structural proteins that give your muscles their strength and function.
Regulating Key Signaling Pathways
At a deeper level, 6′-SL modulates important signaling molecules called FoxO1, FoxO3, and p38. These act like molecular switches that control whether your muscles break down or stay strong. By influencing these pathways, 6′-SL helps tip the balance away from degradation and toward preservation.
Protecting Muscle Fiber Structure
Laboratory studies showed that 6′-SL prevented the reduction in myosin heavy chain (MHC)—the major structural protein in muscle fibers. When MHC levels drop, muscles literally shrink and weaken. By maintaining MHC expression, 6′-SL supports the physical structure that enables muscle contraction and movement.
Real-World Results: From Lab to Living Systems
The most compelling evidence came from mouse studies that tested whether 6′-SL could prevent muscle loss in living animals. Mice given dexamethasone experienced significant muscle atrophy: their muscle fibers shrank, muscle weight decreased, and physical performance declined on tests measuring grip strength, coordination, and endurance.
But mice that received oral 6′-SL supplementation (500 mg/kg) alongside the dexamethasone showed remarkable protection. Their muscle fiber diameter remained larger, muscle weight loss was prevented, and functional tests like grip strength and rotarod performance improved significantly compared to mice receiving dexamethasone alone.
These findings suggest that 6′-SL doesn’t just affect isolated muscle cells in a dish—it can support muscle health in complex living systems, potentially offering similar benefits for humans facing age-related muscle decline.
What This Means for Aging Adults
The implications are profound. As our population ages, finding safe, effective ways to maintain muscle mass and function becomes increasingly critical. While exercise and adequate protein intake remain foundational strategies for combating sarcopenia, emerging nutritional approaches like 6′-SL supplementation may offer additional support.
The beauty of 6′-SL lies in its safety profile. As a natural component of human breast milk, it’s a substance that newborns consume daily. Research has confirmed its safety for oral consumption in adults, rats, and piglets, with no significant adverse effects reported.
Current recommendations for preventing muscle weakness include progressive resistance training and consuming 20-35 grams of protein at each meal—roughly the amount in 4 ounces of meat or fish. Combining these evidence-based lifestyle approaches with targeted nutritional support may offer the most comprehensive strategy for maintaining strength and independence as we age.
Looking Forward: The Future of Muscle Health Support
While the research on 6′-SL and muscle atrophy is promising, scientists emphasize that more human studies are needed to fully understand its effects in elderly populations. The molecular mechanisms revealed in these studies—particularly 6′-SL’s ability to regulate the ubiquitin-proteasome pathway—open exciting possibilities for developing targeted nutritional interventions.
That’s why Siallac® Muscle Health was developed—to harness the science-backed potential of 6′-SL for supporting muscle strength and resilience as we age. Rather than accepting muscle loss as an inevitable part of aging, emerging research suggests we may have more control than we thought.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Go, H., Nam, J.S., Choi, J., Kim, L., & Park, E.J. (2024). 6′-sialyllactose prevents dexamethasone-induced muscle atrophy by controlling the muscle protein degradation pathway. Biochemical and Biophysical Research Communications, 736, 150892. https://doi.org/10.1016/j.bbrc.2024.150892
- Dent, E., Morley, J.E., Cruz-Jentoft, A.J., et al. (2018). International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis and management. Journal of Nutrition, Health and Aging, 22, 1148-1161. https://doi.org/10.1007/s12603-018-1139-9
- Yeung, S.S.Y., Reijnierse, E.M., Pham, V.K., et al. (2019). Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 10, 485-500. https://doi.org/10.1002/jcsm.12411
- Sartori, R., Romanello, V., & Sandri, M. (2021). Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nature Communications, 12, 330. https://doi.org/10.1038/s41467-020-20123-1
- Cleveland Clinic. (2025). Sarcopenia (Muscle Loss): Symptoms & Causes. https://my.clevelandclinic.org/health/diseases/23167-sarcopenia
- Petermann-Rocha, F., Balntzi, V., Gray, S.R., et al. (2022). Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 13, 86-99. https://pmc.ncbi.nlm.nih.gov/articles/PMC3060646/
- Office on Women’s Health. Sarcopenia. U.S. Department of Health and Human Services. https://womenshealth.gov/sarcopenia
- Bodine, S.C. & Baehr, L.M. (2014). Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. American Journal of Physiology-Endocrinology and Metabolism, 307(6), E469-E484. https://pmc.ncbi.nlm.nih.gov/articles/PMC4166716/
- Gumucio, J.P. & Mendias, C.L. (2013). Atrogin-1, MuRF-1, and sarcopenia. Endocrine, 43(1), 12-21. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586538/
- Larsson, S.C. (2023). Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism: Clinical and Experimental, 144, 155533. https://www.metabolismjournal.com/article/S0026-0495(23)00136-1/fulltext
- Anker, S.D., Morley, J.E., & von Haehling, S. (2016). Welcome to the ICD-10 code for sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 7(5), 512-514.
- WebMD. (2024). Sarcopenia (Muscle Loss With Aging): Causes, and Treatments. https://www.webmd.com/healthy-aging/sarcopenia-with-aging
- Clavel, S., Coldefy, A.S., Kurkdjian, E., et al. (2006). Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Anterior muscle. Mechanisms of Ageing and Development, 127(11), 794-801. https://www.sciencedirect.com/science/article/abs/pii/S0047637406001709
- Tyganov, S.A., Mochalova, E.P., Belova, S.P., et al. (2019). Atrogin-1/MAFbx mRNA expression is regulated by histone deacetylase 1 in rat soleus muscle under hindlimb unloading. Scientific Reports, 9, 10263. https://www.nature.com/articles/s41598-019-46753-0
- Haran, P.H., Rivas, D.A., & Fielding, R.A. (2012). Role and potential mechanisms of anabolic resistance in sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 3(3), 157-162.
